Ovarian tissue cryopreservation as fertility preservation after childhood cancer treatment followed by long-term observation after storage.

Ovarian tissue cryopreservation as fertility preservation after childhood cancer treatment followed by long-term observation after storage. - Ovarian cryopreservation for cancer children

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1050220005

Enrollment

100

Registered

2022-04-22

Start date

2022-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer in children and AYA Childhood cancer, CAYA

Interventions

Before the initiation of treatments for childhood cancer, one side of the ovary is surgically removed and then cryopreserved. Patients regularly visit a long-term follow-up center after cancer treatme

Ovarian tissue cryopreservation, OTC

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Diagnose as childhood cancer or disease requiring hematopoietic stem cell transplantation. 2. Without previous chemotherapy and radiotherapy, or with previous treatments which minimally affect ovarian function. 3. Cancer treatments which expected to cause ovarian dysfunction at a high rate are planned. 4. Expected to survive 5-year after cancer treatment (Probability does not matter) 5. Not eligible for other fertility-preserving treatments. 6. One side of the ovary is retained even after ovariectomy. 7. Delay in initiation of cancer treatment due to OTC does not affect cancer outcome. 8. Written informed consent has been obtained from the patients and/or their guardians.

Exclusion criteria

Exclusion criteria: 1. Clear tumor infiltration or metastasis to the ovary. 2. Severe ovarian dysfunction at the time of ovarian tissue cryopreservation because of cancer treatments, etc. 3. No uterus due to tumor resection, etc., or severe uterus dysfunction will be expected due to cancer treatments. 4. Severe neurocognitive impairment is observed or will be expected after cancer treatments.

Design outcomes

Primary

Measure	Time frame
The implementation rate of autologous ovarian transplantation among patients who underwent ovarian tissue cryopreservation.	—

Secondary

Measure	Time frame
1. Days of hospital stay for ovarian tissue cryopreservation and autologous ovarian transplantation. 2. Incidence of complications associated with ovarian tissue cryopreservation and autologous ovarian transplantation. 3. 10-year overall survival of patients who underwent ovarian tissue cryopreservation. 4. Pregnancy rate and production rate after autologous ovarian transplantation. 5. Recovery rate of endocrine function after autologous ovarian transplantation.	—

Measure

Time frame

1. Days of hospital stay for ovarian tissue cryopreservation and autologous ovarian transplantation. 2. Incidence of complications associated with ovarian tissue cryopreservation and autologous ovarian transplantation. 3. 10-year overall survival of patients who underwent ovarian tissue cryopreservation. 4. Pregnancy rate and production rate after autologous ovarian transplantation. 5. Recovery rate of endocrine function after autologous ovarian transplantation.

—

Contacts

Public ContactKai Yamasaki

Osaka City General Hospital

ka-yamasaki@med.osakacity-hp.or.jp+81-6-6929-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026